glp-1 receptor agonists and cancer risk in adults with obesity a major new JAMA Oncology study, researchers examined health records from 86,632 obesity, comparing those who used (like semaglutide or tirzepatide) to matched non-users. The findings Many adults stop GLP-1 therapy
Description
95% CI 0.79 0.99

After 22 people at risk of developing diabetes took Cinnulin PF or a placebo for 12 weeks, Ziegenfuss and colleagues compared the two groups
210,211 The weight loss effects from GLP-1 RA treatment may reverse these changes and alter the pharmacokinetics of co-administered lipophilic drugs by decreasing the Vd (Figure 3)
Exenatide extended-release (ER) , taken weekly: FDA-approved under the brand name Bydureon to treat type 2 diabetes

The Gila monster's bite may be agonising, but humans have been using the lizard's venom to save lives
